September 5, 2024
Paris-based HEPTA Medical Raises €5.7M in Series A to Advance Lung Cancer Treatment
HEPTA Medical, a private medical device company based in Paris, has successfully raised €5.7 million in its Series A funding round, aimed at advancing its innovative treatment for early-stage lung cancer. The round was led by Bpifrance, with participation from M&L Healthcare Investments and Cléry. The funds will be used to secure U.S. regulatory approval and drive the clinical development of HEPTA's cutting-edge microwave ablation platform.
About the company
Founded in 2017, HEPTA Medical specializes in developing a minimally-invasive microwave ablation platform for the treatment of lung cancer. The platform, which features a proprietary temperature sensor, allows for real-time monitoring and control of the ablation process. With lung cancer being the leading cause of cancer-related deaths globally, HEPTA Medical’s platform aims to address the urgent need for more efficient, incision-less treatments, especially for early-detected patients.
Purpose of financing
The Series A funding will allow HEPTA Medical to begin the U.S. regulatory approval process for its device. Additionally, the funds will be directed toward clinical trials to further validate the efficacy and safety of the microwave ablation platform. The company is committed to making lung cancer treatment more accessible and effective through its innovative technology, which can be seamlessly integrated into existing lung navigation systems.
What the company’s official has to add
Dr. Thomas Bancel, CEO of HEPTA Medical, expressed his gratitude for the support of their new investors: “We are excited to push our microwave ablation therapy forward and look forward to reaching new milestones. This funding will accelerate our path towards clinical validation and commercialization, particularly in the U.S. market.”
What the investors have to comment
Philippe Boucheron, Deputy Chief of Life Sciences Investments at Bpifrance, emphasized the importance of HEPTA's work: “HEPTA Medical is at the forefront of minimally invasive lung cancer treatments, and their microwave ablation technology has the potential to significantly improve patient outcomes. We are proud to support their efforts and believe they will achieve groundbreaking results in the near future.”
Conclusion
With the backing of experienced investors like Bpifrance, M&L Healthcare Investments, and Cléry, HEPTA Medical is positioned to revolutionize lung cancer treatment by providing a faster, safer, and more controlled ablation process. The company plans to use the funds to solidify its presence in the U.S. market and continue developing its technology for a broader range of applications.
LinkedIn